TLR2-IN-C29

C29 is a Toll-like receptor 2 (TLR2) inhibitor.

Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR)

Research Areas >> Inflammation/Immunology

TLR2[1]

C29 blunts hTLR2/1 and hTLR2/6 signaling in HEK-TLR2 Stable transfectants and THP-1 Cells. C29 blocks P3C- and P2C-induced IL-8 mRNA dose-dependently in HEK-TLR2 stable transfectants. C29 also inhibits P3C- and P2C-induced IL-1β gene expression significantly at both 1 h and 4 h following stimulation, as well as both P3C- and P2C-induced NF-κB–luciferase activity in transiently transfected HEK293T cells expressing hTLR2 and an NF-κB–sensitive luciferase reporter construct. C29 preferentially inhibits TLR2/1 signaling in primary murine macrophages. C29 blocks TLR2 bacterial agonist-induced proinflammatory gene expression in HEK-TLR2 Cells and murine macrophages. C29 inhibits ligand-induced interaction of TLR2 with MyD88 and blocks MAPK and NF-κB activation[1].

[1]. Vogel S, et al. Small molecule inhibitors of tlr2 signaling. WO2016164414A1

TAK-242 | Chloroquine diphosphate | Resiquimod | imiquimod | Hydroxychloroquine sulfate | GS-9620 | Motolimod | CU CPT 22 | Atractylenolide I | E6446 dihydrochloride | CU-CPT17e | Paquinimod | Gardiquimod trifluoroacetate | Procyanidin B1 | TLR7/8 agonist 1 dihydrochloride